SANGUI(906757)- unterbewerteter geht's nicht!!

FAST HEALING VLU WITH GRANULATION HEMOGLOBIN SPRAY AND ANTIMICROBIAL DACC DRESSINGS
http://ewma.org/english/ewma-conferences/...nic-poster-abstracts.html


FAST HEALING VLU WITH GRANULATION HEMOGLOBIN SPRAY
AND ANTIMICROBIAL DACC DRESSINGS

Roxana Mitu

Bio Hygiene medical services (Bucharest, Romania)

Aim: Clean the wound and close the VLU

Method:
68 years old patient, male, has an open VLU for more than 90 days. The
infection and fibrin were removed with dressings*; the wound was cleaned only with
saline solution and sterile hypoallergenic liquid soap. After removing the slough and
fibrin, was applied He
moglobin Granulation Spray and covered with a breathable
silicone and foam dressing with absorbing capacity.

Result:
The VLU was closed less than 20 days. The dressings were applied between
3-5 days in home care services. A thin layer of antimicrobial gauze* kept the balance of
the wound bed in order the Hemoglobin Spray to come up on a proper wound bed and
supply oxygen to the new granulated tissues.

Conclusion:
The synergy between the dressings* and the Hemoglobin Spray offered
extraordinary results, very fast achieved, less than 20days, as can be seen in the
pictures. The hemoglobin spray is acting properly when the environment is not harmful
with infection or fibrin. All the costs and efforts were convenient relative to the results.

Reference/Used Products ? brand names:
Granulox (Hemoglobin Spray to eliminate hypoxia), Cutimed Siltec (Breathable Silicon Foam), Cutimed Sorbact
Hydroactive (antimicrobial* and debridement tool), Cutimed Sorbact gauze (preventive antimicrobial* thin layer),
Codex (sterile liquid soap)

*DACC

http://ewma.org/fileadmin/user_upload/EWMA/...014_Abstracts/EP623.pdf

New case series looks at innovative haemoglobin spray treatment5th November 2014 The case reports included in this document explore the use of Granulox® haemoglobin spray (infirst Healthcare) for the treatment of patients with chronic and acute wounds. The importance of oxygenation and tissue perfusion to the wound-healing process is well known and it is recognised that oxygen demand increases during the process of tissue repair. However, underlying comorbidities that patients with wounds might have, such as chronic venous insufficiency (CVI), peripheral artery occlusive disease and diabetes, lessen the oxygen supply via the vascular system. In addition, oxygen from outside might be prevented from reaching the wound bed due to the physical barrier of exudate production. Haemoglobin naturally binds and then releases oxygen. ..... ..... ..... http://woundcare-today.com/news/in-brief/...emoglobin-spray-treatment Use of Granulox® haemoglobin spray in clinical practice: case report series http://woundcare-today.com/support/uploads/...20report%20document.pdf

Zitat:
Und bei dem Kurs macht man da nichts verkehrt. Ein Biotechunternehmen mit einem auslizensierten Produkt am Markt und einer MK von gerade einmal 11 mio Euro. Wo gibt es so etwas sonst?

Du meinst also "unterbewertet" ?

Simple and ingenious: use haemoglobin to heal chronic wounds

Seite 55

http://ewma.org/ongoing/Journal/Journal_2_2014_Final.pdf

The EWMA Journal
ISSN number: 1609-2759
Volume 14, No 2, October, 2014

NEWSSangui Biotech International erhält offizielle Bestätigung: Handel auf neu formiertem OTCQB gesichert

Witten, 06. November 2014 - Die OTC Markets Group, Trägerin und Betreiberin mehrerer Freiverkehrsplattformen in USA, hat der Sangui Biotech International, Inc., formell mitgeteilt, dass ihr Antrag zur Einbeziehung in den Handel auf OTCQB, dem Venture Markt für junge und Entwicklungsunternehmen mit heutiger Wirkung angenommen wurde. Nach der Reorganisation der OTC-Märkte, die gerade auf OTCQB zu deutlich verbesserten Transparenzniveaus und zusätzlichen Dienstleistungen und Funktionen für Emittenten und Investoren führte, hat Sangui alle erforderlichen Unterlagen eingereicht und sämtliche Anforderungen an die erstmalige Einbeziehung in den neuen Handel erfüllt.

Ab heute werden die handelbaren Aktien der Sangui Biotech International, Inc. mit offizieller Bestätigung auf dem OTCQB Venture Markt für junge und Entwicklungsunternehmen gehandelt (OTCQB:SGBI). Die hier vertretenen Unternehmen erfüllen ihre Berichtspflichten und unterziehen sich und ihr Management einer jährlichen Überprüfung. Anleger finden Echtzeitkurse und Marktdaten des Unternehmens auf www.otcmarkets.com

OTC Markets Group Welcomes Sangui BioTech International to OTCQB

Nov 06, 2014
OTC Disclosure & News Service
New York, NY 

OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced Sangui BioTech International, Inc.
(OTCQB: SGBI) is verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective November 6, 2014.

http://www.otcmarkets.com/stock/OTCM/news/...tional-to-OTCQB?id=90916